Akums‍‌‍‍‌‍‌‍‍‌ Drugs & Pharmaceuticals Share Price Fall Nearly 3% After Reporting Slightly Lower Q2 YoY

New Delhi, November 14, 2025 – Today’s trading session saw shares of Akums Drugs and Pharmaceuticals Ltd drop by nearly 3% to close in the red. The move has been attributed to its Q2 FY26 performance, which shows most key financial parameters reporting a minor year-on-year decline.

Q2 FY26 Financial Results Mark a Slight Decline

The company reported a consolidated revenue of ₹1,018 crore for Q2 FY26, which was marginally lower than ₹1,033 crore in the same quarter of the previous fiscal, down 1.45 percent. EBITDA shrank at a faster pace to ₹94 crore from ₹121 crore, down 22.3 percent. Adjusted PAT was down to ₹43 crore against ₹67 crore in Q2 FY25, thus down 35.8 percent. A drop was seen across revenue, margins, and profitability, which was the key reason for the stock’s decline in today’s session.

Market Reaction and Trading Trend

The stock closed at ₹426.40, down by 2.51%. The VWAP of the stock stood at ₹419.71 while the total traded volume stood at 155,000 shares. The counter has kept itself near its 52-week low of ₹405.00 and is away from its 52-week high of ₹705.70, which signifies that the sell-off in it has been consistent during the last several weeks.

Operational Highlights Temper Sentiment

While the company’s overall financial performance was weaker, it announced some important operational milestones in its quarterly communication. CDMO revenue came in at ₹ 804 crore, riding on a 7% improvement in volumes, while domestic branded formulations revenue reached ₹ 122 crore with the help of margin improvement. Besides this, the company also announced its Zambia joint venture and confirmed the first commercial supply of formulations to Europe, an indication of further international expansion. However, these positive pieces of news were not enough to mitigate the market’s negativity caused by the YoY decline in earnings.

Akums Drugs & Pharmaceuticals Ltd. is the largest CDMO in India, with four revenue streams: contract development and manufacturing services, domestic branded formulations, and branded exports. The company is listed on both NSE and BSE and remains the largest player in the pharmaceutical outsourcing ecosystem, though the latest quarterly results have made the ‍‌‍‍‌‍‌‍‍‌ investors cautious.

REF: https://nsearchives.nseindia.com/corporate/NSEAKUMS10_13112025173505_AKUMSPRESSRELEASE.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations